SOURCE: Daxor Corp.

January 25, 2007 08:30 ET

Daxor Announces Florida Cardiovascular Institute of Tampa, FL Acquires BVA-100 Blood Volume Analyzer

NEW YORK, NY -- (MARKET WIRE) -- January 25, 2007 -- Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from the Florida Cardiovascular Institute of Tampa, Florida.

The Florida Cardiovascular Institute (FCI) provides state-of-the-art, compassionate health care ranging from preventative medicine to the treatment of the most complex heart and vascular diseases. As the region's only private cardiology practice offering a blood volume analysis (BVA), FCI reaffirms its commitment to providing the highest quality health services available. Through the years, FCI Heart Center has earned its highly regarded reputation in the community by integrating the latest technology and most effective techniques into treatment so their patients can lead healthier and more active lives.

"We are extremely excited to begin working with FCI, especially as this will be Daxor's first BVA-100 within a private practice setting in Florida," noted John Reyes-Guerra, Daxor's Vice President of Sales and Marketing. Mr. Reyes-Guerra also noted that, "FCI has been an innovator in cardiovascular disease management and treatment through their dedication to patient-oriented research through the Florida Cardiovascular Institute and Research Foundation and their relationships with leading academic and community institutions committed to improving patient care."

The Daxor Blood Volume Analyzer BVA-100 permits FCI to offer its patients along with area physicians treating various heart and vascular diseases to accurately measure and then treat a patient's volume derangement. Previous published studies in heart failure have demonstrated that patients who have had their blood volume diagnosed and treated to a normal blood volume by a BVA have significant improved outcomes than patients who remain "volume overloaded."

Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website

Contact Information

  • Contact Information:
    Stephen Feldschuh
    Chief Operating Officer
    Email Contact

    Diane Meegan
    Investor Relations
    Email Contact